Most people are aware of type 1 and type 2 diabetes, but did you know there is a type 3 diabetes as well! It is a more obscure term. Although it is not an accepted medical diagnosis, type 3 diabetes has been discussed in the literature as a possible relationship between insulin resistance in the brain and Alzheimer's disease. This link has been described to help explain how metabolic disorders impact brain health, causing cognitive decline and dementia.

What is Type 3 Diabetes?

Type 3 diabetes is more of a misnomer because it should not be confused with type 3c diabetes, which relates to pancreatic dysfunction. The term "type 3 diabetes," on the other hand, has been loosely used by some scientists to analogously propose that Alzheimer's disease is strongly implicated with insulin resistance in the brain.

This concept was conceptualized by Dr. Suzanne de la Monte and Dr. Jack Wands of Brown University in the year 2008. This hypothesis postulated that Alzheimer's disease may be called type 3 diabetes for it bears many similarities with glucose metabolism disorder type 2 diabetes. Their concept arises from the basic principle that insulin is fundamental to blood sugar regulation, but it is also the case with the brain. When brain cells become insulin-resistant, they lose access to glucose, impairing their function.

Research published in the Journal of Diabetes Science and Technology supports this hypothesis by indicating that insulin resistance can be a significant contributor to the occurrence of dementia, also referred to as Alzheimer's. The symptoms of memory loss and diminished reasoning are associated with impaired glucose metabolism in the body, especially in the cerebral tissue.

Symptoms of Type 3 Diabetes

Although type 3 diabetes is not a "medical term," its symptoms correlate well with Alzheimer's diseases that are known to reduce the ability to think in an efficient manner and bring down brain health. These signs are:

- Loss of memory, especially short-term.

- Poor judgment and judgment ability

- Failure in recognizing people or places familiar once.

- Failure in the process of reading, writing or processing numbers

- Anxiety, agitation, or mood changes.

- Disorganized thoughts or confusion

- Lack of impulse control

As the disease advances, patients may be afflicted with severe complications including an inability to swallow or control their bodily functions. In the final stages, most patients die from fatal complications such as aspiration pneumonia.

Causes of Type 3 Diabetes

This may not be well understood with regards to type 3 diabetes, or the exact link between insulin resistance and Alzheimer's disease. Some identified contributing factors include the following:

1. Insulin Resistance

Insulin acts as an important regulatory mechanism of brain functions such as memory and cognition. The reduction in insulin signaling may impair metabolism of brain cells, thus bringing about neurodegeneration.

2. Type 2 Diabetes

These diseases show a strong relationship and those individuals diagnosed with type 2 diabetes have double chances of getting Alzheimer's. In the two, the main causes can be chronic inflammation, oxidative stress, and a defect in glucose metabolism.

3. Environmental and Lifestyle Factors

Insulin resistance associated with obesity, stress, and an unhealthy diet is considered a cause that may increase the chances of Alzheimer's disease.

Researches in Frontiers in Neuroscience and The Lancet Neurology have also highlighted that drugs used for antidiabetic medication may be crucial for the prevention or at least slowing down the course of Alzheimer's.

Treatments for Type 3 Diabetes

In 2022, in a study in Pharmaceuticals, researchers studied biomarker uptake in brain regions implicated in the faulty uptake and metabolism of blood sugar in Alzheimer’s patients.

Emerging Therapies

Research into such treatments as intranasal insulin has also been promising. Intranasal delivery of insulin directly to the brain has been reported to enhance glucose uptake by brain cells, improve memory, and boost cognitive performance. While such clinical trials have been shown to be successful, additional research is needed for safety and efficacy.

Medications

For patients being aggressive or agitated, antipsychotic drugs may be prescribed; however, therapies such as cognitive rehabilitation as well as cognitive stimulation therapy serve to preserve memory and executive function.

Lifestyle Interventions

Diet, exercise, and stress management are critical in preventing and managing insulin resistance. A review in the Journal of Alzheimer's Disease also highlighted the benefits of Kirtan Kriya meditation, which can regulate genes involved in insulin and glucose metabolism, improve sleep, and reduce inflammation.

Can Type 3 Diabetes Be Prevented?

Although type 3 diabetes is not officially recognized, its connection to Alzheimer’s disease underscores the importance of proactive measures for brain health. Some prevention strategies include:

1. Healthy Diet

Consuming a balanced diet rich in antioxidants, whole grains, and healthy fats may support brain health.

2. Regular Exercise

Physical activity improves insulin sensitivity, reduces inflammation, and enhances overall metabolic health.

3. Stress Reduction

Mindfulness practices, including meditation, have been shown to lower stress levels, which can reduce the risk of cognitive decline.

The term type 3 diabetes brings out the complex relationship between metabolic disorders and brain health. Even though it is not a recognized medical condition, the concept emphasizes the crucial role of insulin in brain function and its possible contribution to Alzheimer's disease. Continued research will hopefully provide hope for therapies such as intranasal insulin and lifestyle modifications.

NHS Flu Cases: Flu season has arrived far earlier than expected this year, and hospitals across England are already seeing a sharp rise in cases. The latest figures show that the number of patients admitted with flu is more than 50 percent higher than the same week last year. During the week starting 24 November, an average of 1,717 people were in hospital with flu each day, including 69 who needed critical care, as per The Independent.

In the same week last year, the total was 1,098 patients, with 39 in critical care. These numbers follow recent warnings from the NHS, which urged vulnerable groups to get their flu jabs as early as possible, as experts fear this could turn into one of the most challenging winters in recent memory. This raises several key questions. What is driving this sudden surge, how severe could the coming months be, and how much protection can the vaccine offer?

NHS Flu Cases: What’s Causing The Flu Surge?

Specialists suspect an altered form of influenza A is behind the early rise in cases. They observed Australia’s recent flu season, which often gives a hint of what lies ahead for the UK, and saw record-breaking infection levels. Alerts also came from the Asia-Pacific region, where Japan announced a flu epidemic in October and schools were temporarily closed.

Flu viruses fall into three groups: influenza A (H1N1), influenza A (H3N2), and influenza B. This year, the main culprit is the H3N2 strain. Flu viruses constantly change through a process called antigenic drift, which is why vaccines are updated each year. In the Northern Hemisphere, the strains for the upcoming winter season are chosen in February.

However, this particular H3N2 strain, known as subclade K, changed more rapidly over the summer and is now considered significantly different from the strain used in the current vaccine, according to the UK Health Security Agency (UKHSA). After reviewing the latest NHS numbers, Sarah Woolnough, chief executive of The King’s Fund, noted that the flu season has “not yet peaked,” adding that it is still uncertain how long this early surge will last.

NHS Flu Cases: How Bad Is It?

Health experts fear that thousands of people could lose their lives this winter. Flu-related deaths more than doubled last year, with the UKHSA estimating 7,757 deaths in England, compared with 3,555 the year before. Deaths among children also rose from 34 to 53. Senior NHS leaders have warned of a very difficult winter ahead. In November, NHS England chief executive Jim Mackey said staff may face “one of the toughest” seasons yet.

He admitted that the prospect of a long, heavy flu season had been a major concern, and current trends suggest that these worries were well founded. Australia recorded its worst flu season on record, with more than 410,000 cases, and the expectation is that the UK may face similar patterns. He added that from December through March, hospitals will likely run at full capacity.

NHS Flu Cases: How Effective Are The Vaccines?

The UKHSA has analysed how well this year’s vaccine is performing by examining whether vaccinated people are less likely to be admitted to hospital with flu. Early assessments show that the vaccine is offering around 70 to 75 percent protection against hospital attendance in children aged two to seventeen, and around 30 to 40 percent protection in adults.

Dr Jamie Lopez Bernal, consultant epidemiologist for immunisation at UKHSA, said he remains confident that the vaccine will provide important protection for those most at risk, regardless of which strain becomes dominant. He explained that practising good respiratory hygiene and reducing contact with others when symptomatic can also help lower transmission. According to NHS England, 14.4 million flu vaccines were administered during the autumn, which is more than 160,000 ahead of the same point last year.

NHS Flu Cases: Should You Get A Flu Vaccine?

Flu vaccinations are free and advised for several groups, including:

• Everyone aged 65 and above
• People under 65 who fall into clinical risk categories
• Residents of care homes and their carers
• Pregnant women
• Close contacts of people who are immunosuppressed
• Frontline health and social care workers
• Children

Vaccinations began in October, but anyone eligible can still get their jab until 31 March.

You can get vaccinated by:

• Making an appointment with your GP surgery
• Booking a free NHS flu jab at a pharmacy through the NHS website or app
• Visiting a pharmacy that offers walk-in NHS flu vaccinations if you are 18 or older

As of 23 November, 69.6 percent of people aged over 65 had received their jab. Uptake was lower in other groups, including adults under 65 with long-term health conditions (35.1 percent), pregnant women (33.9 percent), and children aged two (39.8 percent) and three (40.3 percent).

A federal vaccine advisory group in the United States is preparing to decide whether newborns should continue to receive the hepatitis B vaccine, which was the first shot proven to prevent cancer. The CDC committee is expected to revisit the long-standing guidance from the early 1990s, when the vaccine began to be given within the first 24 hours of life.

As per CNN, advisers to the Centers for Disease Control and Prevention will be voting on Friday to vote on whether the agency should move away from its long-held recommendation that every infant receive the hepatitis B shot shortly after birth. The information below outlines key points everyone should understand about hepatitis B and its vaccine.

What is Hepatitis B?

Hepatitis B is a viral infection that affects the liver. Many adults are able to clear the virus after an acute infection. Some, however, go on to develop chronic hepatitis B, which increases the risk of liver cancer, liver failure and cirrhosis, or permanent scarring of the liver.

People who live with chronic hepatitis B face a much higher chance of dying early. At the ACIP meeting on Thursday, Dr. Sandra Fryhofer, who spoke on behalf of the American Medical Association, described her experience working on a hepatitis B ward during medical school, according to CNN.

She said that those were the sickest patients she had ever encountered. She explained that she has treated people with liver disease caused by hepatitis B, cirrhosis linked to the virus, and liver cancer, as well as deaths related to the infection. Infants and young children who contract hepatitis B are far more likely to develop lifelong disease, including about 90 percent of infected babies and roughly 30 percent of children between one and five years of age.

How Is Hepatitis B Spread?

The hepatitis B virus is highly contagious. It spreads when blood, semen or other bodily fluids from a person who carries the virus enter the body of someone who is not infected.

Certain medical conditions, personal habits and other circumstances can raise the risk, such as injection drug use or sexual contact, but the virus can infect anyone. Hepatitis B can also pass from an infected mother to her baby during childbirth, whether through a vaginal delivery or a C section.

How Common Is Hepatitis B?

Many people living with hepatitis B show no clear symptoms, and more than half may not know they are infected. Recent CDC figures report about 2200 newly documented cases of acute hepatitis B in 2023, although the true number is estimated to be more than six times higher, closer to 14400.

The CDC also estimates that about 640000 adults in the United States have chronic hepatitis B. Worldwide, the World Health Organization reports that 254 million people are living with chronic hepatitis B, with about 1.2 million new infections each year.

Can Hepatitis B Be Treated?

There is no treatment for acute hepatitis B. Some medicines are available for chronic infection. These treatments may need to be taken for life because there is no cure.

How Can Hepatitis B Be Prevented?

Vaccination is the most reliable way to prevent hepatitis B. The shots offer strong protection in infancy and continue to shield individuals well into adulthood.

Most people who live with hepatitis B contracted it as babies or very young children, when their immune systems were not fully developed, according to the CDC. At present, the agency recommends that all infants receive the vaccine at birth before leaving the hospital.

Babies usually receive a three dose series. A scientific review by the Vaccine Integrity Project found that 95 percent of healthy infants develop enough immunity after the third dose. The vaccine also lowers the risk of infection by nearly 70 percent in babies born to mothers who have hepatitis B.

More than 90 per cent of people who completed the vaccine series showed signs of continued protection 30 years later, based on CDC data.

Is The Hepatitis B Vaccine Safe?

According to the Vaccine Integrity Project’s review, giving the hepatitis B shot at birth has consistently proven safe. Only mild and short-lasting reactions have been noted, such as slight swelling or redness at the injection site and low fever. There was no rise in serious life-threatening reactions linked to the vaccine.

Dr. Anthony Fiore, an infectious diseases specialist and former CDC official who worked in the hepatitis division, described it as a very safe vaccine. He said it has been studied thoroughly before and after approval. He added that the United States vaccine safety systems have looked closely at concerns about fever or other chronic problems.

He explained that none of these concerns have been confirmed. No long-term harm has been linked to the vaccine, and nothing comes close to the danger posed by chronic hepatitis B infection.

Most of us do not think twice about our daily driving habits. We take the same turns, choose the same roads, and travel at roughly the same times every day. But according to new research from Washington University in St Louis, these small choices may quietly reflect something deeper happening inside the brain. The findings are published in the journal Neurology.

The study suggests that subtle changes in driving behavior could serve as early warning signs of cognitive decline. In other words, the way an older adult drives today may help predict future memory or thinking problems long before they become obvious.

What the Researchers Found

The team focused on people already diagnosed with mild cognitive impairment, often considered a transitional stage between normal aging and conditions like Alzheimer’s disease. They analyzed data from 56 individuals with mild cognitive impairment and compared it with information from 242 adults of similar age who showed no cognitive issues. The average age in both groups was 75.

Instead of relying only on memory tests or conversations with patients, the researchers added GPS tracking data collected directly from participants' vehicles. This allowed them to understand how often people drove, where they went, what routes they chose, and how they behaved behind the wheel over a period of nearly three and a half years.

What emerged was a pattern. People with mild cognitive impairment gradually began driving less often and to fewer places. They stuck to familiar routes, avoided more complex trips, and showed less variation in the times they traveled. They also tended to speed less. Even after adjusting for factors like age, education level, and genetic risk of Alzheimer’s, the differences in driving habits remained clear.

Driving Behavior as a Diagnostic Tool

The researchers found that driving data alone correctly identified individuals with mild cognitive impairment 82 percent of the time. When combined with standard cognitive tests and demographic information, accuracy rose to 87 percent.

Neurology researcher Ganesh Babulal explained that early identification of unsafe drivers is a public health priority, but the usual evaluation methods can be slow and difficult. According to him, adding GPS tracking to traditional screening tools could offer a practical and more accurate way to spot early cognitive problems.

He noted that daily driving behavior is a low effort and unobtrusive marker of how well someone is functioning. Since driving requires quick thinking, coordination, and attention, even small cognitive changes can influence how people choose to navigate the road.

What Comes Next

The research team plans to expand the study to include larger and more diverse groups of people. They also hope to bring in additional factors, such as vehicle type, where participants live, and other medical conditions.

Their goal is not to take away anyone’s independence but to help identify risks earlier so that support and interventions can be offered before a crash or near miss occurs. At the same time, the researchers stress that any tools developed from this work must balance safety with respect for personal autonomy and privacy.

This study opens an important conversation: sometimes the first signs of cognitive decline do not show up in a doctor’s clinic. They show up quietly, in the everyday paths we choose and the roads we avoid.,